Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without Chemotherapy in Black Patients With Advanced NSCLC
NCT06745882Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2025
- Primary completion
- Jan 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06745882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745882.